HOME | CONTACT | BLOG | SITE MAP   

Management Team

Robert J. Harman, D.V.M., M.P.V.M. - Founder, Chief Executive Officer
Dr. Harman has more than 22 years of experience as a chief executive officer and biotechnology entrepreneur in four novel businesses, all financial successes. Dr. Harman is a veterinarian and statistician, and has overseen the completion of more than 1,000 contract research projects in his career for the development of veterinary and human biotechnology products. He has led the following companies: HTI Bio-Services, a contract research company; HTI Bio-Products, a biological reagent and antibody production company; and Animal Health Ventures, a veterinary product licensing company.
Carolyn Wrightson, Ph.D. - Vice President of Operations
Dr. Wrightson has more than 20 years of experience in biochemistry, molecular biology, and molecular pathology. Her expertise lies in scale-up of research technologies into high-throughput services, implementation of regulatory compliance, project management, and product development. Dr. Wrightson has experience in research and development, information systems and process development, lean systems analysis and implementation, intellectual property, and contract management.
Jeffrey Schaffer, D.V.M. - Vice President of Sales, Marketing and Professional Services
Dr. Schaffer obtained his Doctor of Veterinary Medicine at the University of Perugia. He was the Director of Animal Health at PALL Life Sciences, overseeing product distribution with over 100 sales representatives. Dr. Schaffer has over 15 years experience in the Regenerative Medicine field. He was the lead in the development, marketing and launch of the PALL V-PET™ platelet therapy system. Dr. Schaffer has practiced veterinary medicine at Nassau-Suffolk Vet Hospital, several emergency veterinary hospitals and animal shelters and also worked as a professor in medical and biological subjects at numerous colleges and universities in New York. He is the author of a range of published studies and has established relationships with opinion leaders in medical, veterinary research and clinical practice.
Mark Hughes, D.V.M. - Senior Manager, Veterinary Clinical Research and Safety
Dr. Hughes, former Product Development Manager in R&D at Virbac Corporation, brings eight years of experience managing drug development projects through the process of pharmaceutical development, preclinical and clinical trials, and submissions to regulatory authorities for marketing approval in the US and Canada. Dr. Hughes received BS, MS, and DVM degrees from the University of California, Davis, and is licensed to practice in California. He also has provided commercial embryo transfer services for beef and dairy cattle, developed in-vitro diagnostics for diseases in animals and people, and managed a laboratory animal research facility. span>
Kevin Hicok, M.S. - Director, Research and Development
Mr. Hicok has over 20 years of research experience in the field of adult stem and regenerative cell therapeutics, including bone marrow derived and fat derived culture expanded mesenchymal stem cells (MSCs) as well as primary adipose derived regenerative cells. His experience includes R&D positions with Osiris Therapeutics, Artecel Sciences, Cytori Therapeutics, and the Mayo Clinic. With his expereince in managing basic and applied research groups, as well as expertise in applying GLP, GTP and cGMP quality standards to research practice, he supports the development team to gain FDA approval for all allogeneic stem cell therapies. span>
Tony Moore - Director, National Accounts
With nearly three decades of experience in molecular pathology, chemistry, diagnostics, hem path and animal health, Mr. Moore has gained expertise for growing start-up companies, marketing new products, and successfully adapting them into distribution.  Mr. Moore started his career with TAP Pharmaceuticals as a Sales Representative upon graduating from Texas Tech University.  From there Mr. Moore was recruited by BioSite Diagnostics to help launch the first point-of-care diagnostics product line in the human medical market.  Mr. Moore was part of the team that brought the private company to a publicly held position, and is now the leading provider of rapid diagnostics products and antibody development technologies.  Mr. Moore also held positions at Abaxis Diagnostics and Antech Diagnostics, both animal health companies.